Tuberculosis Tag

  • All
  • Advocacy Hub
  • Advocacy Update
  • Blog Posts
  • GHC Announcements
  • News Center
  • Statement
From the Ground Up: NCDs, TB, and Resilient Health Systems

Organized by Global Health Council, NCD Roundtable, Stop TB Partnership, and ACTION

May 23
4:00 PM – 6:00 PM CEST
Club suisse de la presse – Geneva Press Club
106 Route de Ferney
1202 Geneva, Switzerland


Weak health systems that cannot provide a full spectrum of quality care combined with the double burden of NCDs and TB impede economic growth, and undermine progress toward global poverty eradication, including existing and future development goals such as Universal Health Coverage (UHC). With WHO Director-General Tedros making UHC his top priority and with the NCD and TB High-Level Meetings approaching, it is a strategic time for the NCD and TB communities to coordinate efforts and use integrated care to show how health systems can address multiple health challenges in low-resource settings.

ACTION, Global Health Council, NCD Roundtable, and the STOP TB Partnership cordially invite you to a discussion on how the UHC agenda will need to address the double burden of NCDs and TB in low- and middle- income countries.

Featured Speakers

Admiral Brett Giroir, Assistant Secretary for Health, The U.S. Department of Health & Human Services

Opening Remarks: Loyce Pace, President and Executive Director, Global Health Council

Moderator: Amy Israel, Global Health Thought and Leadership Director,  Eli Lilly

Kwanele Asante Shongwe, Chair, Ministerial Advisory Committee on the Prevention and Control of Cancer, National Department of Health, Republic of South Africa

Dr. Sarabjit Chadha, Deputy Regional Director, South East Asia, The International Union Against TB and Lung Disease

Dr. Lucica Ditiu, Executive Director, STOP TB Partnership

Dr. Wilmot James, Visiting Professor, Pediatrics and International Affairs, Columbia University (Former MP, South Africa)

Dr. Janna Patterson, Senior Vice President, Global Child Health,  American Academy of Pediatrics

2018 World TB Day Conference

Organized by
New York City Department of Health & Mental Hygiene, New York University (NYU) School of Medicine, NYC Health & Hospitals/Bellevue, and Rutgers Global Tuberculosis Institute

March 26
Farkas Auditorium, NYU Langone Medical Center
New York, New York


(Registration has now closed)

In commemoration of World TB Day (March 24), this conference will address the history of the TB epidemic in New York City and the path towards TB elimination. Topics will include a review of local epidemiology, infectiousness and transmission of TB, short-course regimens for MDR TB, emerging drugs for TB treatment, strategies for addressing the current state of TB in New York City.

Keynote speakerDr. Tom Frieden, President and Chief Executive Officer of Resolve at Vital Strategies

Our other esteemed presenters include:

1) Dr. Charles Daley from National Jewish Health
2) Dr. Mengchun Li from TB Alliance
3) Dr. Edward Nardell from Harvard T.H. Chan School of Public Health
4) Dr. Lee Reichman from Rutgers Global Tuberculosis Institute

A detailed agenda will be available closer to the event.


New Hope for Children with TB

This blog was written by the communications team at TB Alliance as part of Global Health Council’s Member Spotlight SeriesGlobal Alliance for TB Drug Development (TB Alliance) is a not-for-profit organization dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. TB Alliance is a 2018 Global Health Council member.

Each year, 1 million children get sick with tuberculosis (TB) and about 210,000 needlessly die. Those grim statistics translate to nearly 600 children dying on a daily basis.

TB Alliance and partners are working to solve this problem. Until recently, children didn’t have access to TB medicines in the proper doses or formulations. Care providers and parents crushed or chopped adult pills to approximate the right dose for children. This makes for a daily struggle—for six long months—and creates a guessing game of whether children receive the right dose. Ultimately, this approach can negatively impact adherence, outcomes and fuel the development of drug-resistant TB.

Improved drugs are solving this problem. TB Alliance has introduced new TB cures for children in the correct dose and child-friendly forms, and health systems around the world are working to ensure that they are available widely.

Here’s where we stand today:

1) More than 700,000 treatment courses have been ordered.
2) Close to 80 countries have adopted the improved medicines.
3) The improved medicines have been prequalified by the World Health Organization.
4) A major opportunity now exists to integrate childhood TB into maternal and child health efforts.

These new medicines are having a real-world impact. In Nairobi, three-year-old Chelsea was among the first in the world to be treated and cured with them. Read her story here.

Read more about the project to develop and launch these improved pediatric TB medicines in New Pathways for Childhood TB Treatment.

As we mark World TB Day on March 24, the global health community has some cause to celebrate. But there’s still work to be done. Drug-resistant TB is a growing threat, and today’s treatments are woefully inadequate. Treating drug-resistant TB in adults and children alike means thousands of often toxic drugs and hundreds of injections for 9 months to two years or even longer.

TB Alliance is developing new drug regimens to reshape the treatment landscape for every person with TB. Political momentum is beginning to build; events like the upcoming U.N. High-Level Meeting on Tuberculosis in September present an opportunity for global leaders to make meaningful commitments to fund the research and development needed to bring about the drug, diagnostics and vaccines that can truly render TB a disease of the past.